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Contrast Induced Nephropathy (CIN) is a feared complication of numerous radiological procedures that expose patients to
contrast media. The most notorious of these procedures is percutaneous coronary intervention (PCI). Not only is this a leading
cause of morbidity and mortality, but it also adds to increased costs in high risk patients undergoing PCI. It is thought to result
from direct cytotoxicity and hemodynamic challenge to renal tissue. CIN is deﬁned as an increase in serum creatinine by either
≥0.5mg/dLorby ≥25%frombaselinewithintheﬁrst2-3daysaftercontrastadministration,afterothercausesofrenalimpairment
have been excluded. The incidence is considerably higher in diabetics, elderly and patients with pre-existing renal disease when
compared to the general population. The nephrotoxic potential of various contrast agents must be evaluated completely, with
prevention as the mainstay of focus as no eﬀective treatment exists. The purpose of this article is to examine the pathophysiology,
risk factors, and clinical course of CIN, as well as the most recent studies dealing with its prevention and potential therapeutic
interventions, especially during PCI. The role of gadolinium as an alternative to iodinated contrast is also discussed.
1.Introduction
There is a high prevalence of Chronic Kidney Disease (CKD)
in Patients with Coronary Artery Disease (CAD), ranging
from 23%–46% in diﬀerent studies [1–3]. Patients with
CKD also have a higher risk of cardiovascular events than
the general population [4–6]. Also, cardiovascular disease
accounts for more than half of end-stage renal disease
(ESRD) deaths [7]. Reduced renal function has been seen
to be independently associated with risk of death, cardiovas-
cular events, and hospitalization in large, community-based
populations [6, 8].
The incidence of renal insuﬃciency in this high-risk
group of population undergoing coronary intervention is
on the rise due to the use of radiographic contrast in
increasingly complex cardiac interventional procedures [9].
This has a direct consequence on mortality as seen by Brown
et al. who showed that a transient as well as persistent
postprocedural renal dysfunction was prognostically signif-
icant for mortality during extended followup [10]. Renal
function is directly related to mortality in patients with acute
myocardial infarction undergoing Primary Percutaneous
CoronaryIntervention(PCI)-lowertheCreatinineClearance
(CrCl); lesser is the survival after Primary PCI [11].
This paper covers the latest update on contrast-induced
nephropathy among patients undergoing PCI.
2. Deﬁnition
Contrast-induced nephropathy (CIN) after PCI has multiple
deﬁnitions in the medical literature [12, 13]. Due to these
diﬀerent deﬁnitions used across literature, existing data on
this clinical entity is inconsistent. Harjai et al. attempted
to identify the optimal deﬁnition of CIN by assessing the
prognostic signiﬁcance of 4 commonly used contemporary
deﬁnitions of CIN (increases in serum creatinine after PCI
[Cr] >1.0mg/dL, >0.5mg/dL, and >25% after PCI; and
the American College of Cardiology National Cardiovas-
cular Data Registry deﬁnition which deﬁnes it as a 2-fold
increase in serum creatinine to >2.0mg/dL or a need for
d i a l y s i sa f t e rP C I[ 14]) with respect to 6-month major
adverse cardiovascular events and all-cause mortality. Only2 Cardiology Research and Practice
2 deﬁnitions ([Cr] ≥0.5mg/dL, ≥25%) consistently pre-
dicted adverse events after PCI [15]. Therefore, a complete
deﬁnition for CIN encompasses absolute (≥0.5mg/dL) and
relative increase (≥25%) in serum creatinine at 48–72 hours
after exposure to a contrast agent compared to baseline
serum creatinine values, when alternative explanations for
r e n a li m p a i r m e n th a v eb e e ne x c l u d e d[ 9].
3. Incidenceof CIN
Based on these deﬁnitions, the overall incidence of CIN in
the general population has been estimated to lie between
1%–6% [16]. The ﬁgure is higher when CIN follows PCI. In
their retrospective analysis of the Mayo Clinic PCI registry
comprising of 7586 patients, Rihal et al. found the incidence
for general population undergoing PCI to be 3.3% and
dialysis was needed in 0.3% [17]. However, incidence of CIN
rises up to 20% or more in selected patient subsets, especially
in patients with underlying cardiovascular disease [9].
4. Pathogenesis of CIN
Although the pathogenesis of CIN is not well understood,
there is increasing evidence that it occurs as a combination
of direct toxicity to the renal tubular epithelium, oxidative
stress, ischemic injury, and renal tubular obstruction [18–
20]. Also, increased intratubular pressure secondary to
contrast-induced diuresis and increased perivascular hydro-
static pressure may lead to medullary hypoxia through lower
medullary blood ﬂow [21]. Renal ischemia may be the result
of an imbalance between vasoactive substances (Adenosine
and Endothelin) and vasodilators (NO and Prostaglandins)
[19].
Signiﬁcant urine volume is needed to clear the high
osmotic load of the contrast medium. Exposure to this
high osmotic load results in characteristic histopathological
changes of osmotic nephrosis, a morphological pattern with
vacuolization and swelling of the renal proximal tubular cells
[22]. In a study, this ﬁnding was seen in almost a quarter
(22%) of patients undergoing renal biopsy within 10 days of
contrast exposure [23].
5. Risk Factorsof CIN
The risk factors of CIN have been extensively studied in the
past and can be classiﬁed into modiﬁable and nonmodiﬁable
risk factors. These have also been subdivided into “patient
related” and procedure related and are tabulated in Table 1.
5.1. Age. The elderly remain at a higher risk of CIN after
PCI, although the reason has not been elucidated yet. It is
believed to be multifactorial, including age-related reduction
in glomerular ﬁltration rate (GFR), tubular function, as well
as more diﬃcult vascular access requiring greater amount
of contrast, presence of multivessel disease, and comorbids.
A few studies have found age older than 70 years to be an
independent predictor of CIN in multivariate analysis [24–
26].
5.2. Pre-existing Renal Disease. Baseline elevated serum
creatinine was found to be an independent predictor of
CIN in numerous studies. Increase in baseline Cr level to
1.2mg/dL or higher resulted in an exponential increase in
the risk of nephrotoxicity [27]. Risk of developing CIN after
undergoing PCI rises with lowering GFR [28].
5.3. Diabetes Mellitus. Many studies have found Diabetes
Mellitus (DM) as an independent risk factor for CIN
in studies [17, 26, 29]. This risk is also independent of
preexisting renal dysfunction [26, 30]. The incidence of CIN
in diabetics varies from 5.7% to 29.4% [30, 31]. Given an
increasing prevalence of DM in the general population and
a higher risk of vascular disease among this group, diabetic
patients represent a major fraction of patients requiring
radiological procedures with use of contrast including PCI.
Toprak et al. showed that in patients with preexisting renal
insuﬃciency, Diabetes Mellitus independently increased the
risk of development of CIN and need for dialysis as opposed
to pre-DM and Normal Fasting states [32], while Berns
showed that the incidence of CIN in diabetics was higher if
Cr > 4 . 0c o m p a r e dt oC rb e t w e e n2 . 0a n d4 . 0m g / d L .C l e a r l y ,
there is a synergistic eﬀect of diabetes and pre existing renal
insuﬃciency [33].
5.4. Cardiac Risk Factors. Congestive Heart Failure, Anterior
MI, Cardiogenic Shock, and Use of Intra-aortic Balloon
Pump have all been associated with increased risk of CIN
after PCI, mainly because they all lead to Reduced Renal
Perfusion [17, 26, 34, 35].
5.5. Volume of Contrast. Volume of contrast remains the
primary modiﬁable risk factor. Increasing complexity of
coronary intervention invariably has led to higher volumes
usedperprocedureandthisoverallaugmentstheriskofCIN.
Many studies have documented a clear correlation between
volume of contrast and risk of CIN [24, 36–38]. There is
also an association of CIN with closely placed procedures
which ultimately translates into an increased amount of
contrast used cumulatively [36]. McCullough et al. showed
that the risk of CIN is minimal in patients receiving less than
100mL of contrast media during procedures, or the volume
of contrast used is <5mL/kg/Serum Cr [29].
However, whether incidence of CIN is dose related or not
has also been studied. In their study of 118 patients with
Cr >1.3 and pre existent renal disease, Mekan et al. found
that the contrast-induced reduction in renal function was
not signiﬁcantly higher with a higher volume of contrast
(>100mL)[39].Ontheotherhand,Kaneetal.demonstrated
a signiﬁcant rise in incidence of CIN with increase of volume
of contrast [38]. The ratio of the volume of contrast media
to the creatinine clearance (V/CrCl) has been correlated with
the area under the curve of contrast media concentration
over time. With that concept, Laskey et al. showed that
a V/CrCl ratio >3.7 was a signiﬁcant and independent
predictor of an early abnormal increase in serum creatinine
after PCI in an unselected population of 3,179 patients
[40].Cardiology Research and Practice 3
Table 1: Risk factors for development of contrast-induced nephropathy.
Nonmodiﬁable Modiﬁable
Patient-related factors
Age
Diabetes mellitus with CRF
Preexisting renal failure Volume depletion
Congestive heart failure Anemia, PCI related blood loss
Hemodynamic instability Nephrotoxic drug use
Nephrotic syndrome Low serum albumin
Renal transplant
Procedure-related factors
IABP Volume of contrast media
Emergent/primary PCI Multiple administration of CM within 72 hours
Intraarterial CM administration Osmolality and ionicity of CM
CM, contrast media; CRF, chronic renal failure; IABP, intra-aortic balloon pump; PCI, percutaneous coronary intervention.
5.6. Type of Contrast. Another important factor contributing
to risk of CIN is the type of contrast used, with osmolality
playing the key role. Other diﬀerences in contrast media
including ionicity and viscosity may also be involved.
Properties of contrast media are listed in Table 2.
Ametaanalysisof31trialslookingatCINandosmolarity
of contrast used revealed that the incidence of CIN was
signiﬁcantly higher with high osmolar contrast use in
patients with pre existing renal insuﬃciency. In patients
without renal disease it was not signiﬁcantly diﬀerent [41].
This was reconﬁrmed by Rudnick et al. who compared low-
osmolar nonionic contrast agent, iohexol, and the high-
osmolar ionic contrast agent, diatrizoate, in 1,196 patients
undergoing cardiac angiography. They found that acute
contrast nephrotoxicity was signiﬁcantly higher in patients
receiving diatrizoate. Again, this diﬀerence was limited to
patients with previous renal insuﬃciency or renal insuﬃ-
ciency combined with diabetes mellitus [42].
The advent of iso-osmolar contrast was further promis-
ing. In a randomized, double-blind, prospective, multicenter
study, Aspelin et al. compared the nephrotoxic eﬀects of an
iso-osmolar, dimeric, nonionic contrast medium, iodixanol,
with those of a low-osmolar, nonionic, monomeric con-
trast medium, iohexol in a group of 129 diabetic patients
with serum creatinine concentrations of 1.5 to 3.5mg per
decilitre, and showed that nephropathy induced by contrast
medium may be less likely to develop in high-risk patients
when iodixanol is used rather than a low-osmolar, nonionic
contrast medium [43]. Another meta-analysis of pooled data
of 16 double-blind, randomized, controlled trials from 2727
patients comparing iso-osmolar contrast medium iodixanol
with low-osmolar contrast media was conducted [44]. The
maximum rise of Serum Creatinine and frequency of CIN
were both signiﬁcantly lower in patients using iso-osmolar
contrast. This was seen in all patients: renal insuﬃciency
patients and in patients with combination of renal insuﬃ-
ciency and diabetes mellitus. Independent predictors of CIN
included CKD, DM + KD and use of low osmolar contrast
media.
Two recent trials looked at the incidence of CIN in CKD
patients with use of iso-osmolar and low-osmolar contrast
agents [45]. In the RECOVER trial, the incidence of CIN
was signiﬁcantly lower with iodixanol (7.9%) than with
ioxaglate (17.0%; P 1/4 0.021). However, the ICON trial
showed no signiﬁcant diﬀerence in incidence of CIN [46].
The controversy continued with the CARE [47] and the
NEPHRICtrialswiththeformershowingnodiﬀerenceinthe
incidence of contrast-induced nephropathy in CKD patients
treated with iopamidol or iodixanol, and the latter revealing
iodixanol to be superior to iohexol in patients with CKD and
DM [48].
In the most recent multicenter, double-blind, ran-
domized, parallel-group ACTIVE trials, 148 patients with
moderate-to-severe chronic kidney disease, undergoing
contrast-enhanced multidetector computed tomography of
the liver, were randomized to either the low-osmolar agent
iomeprol-400 or iodixanol-320. The incidence of CIN as well
as mean rise in serum creatinine was signiﬁcantly higher in
the patient group receiving iodixanol [49].
Generally the use of iso-osmolar contrast agents is safer
and leads to lower rates of CIN in patients at high risk of
developing acute kidney damage. However, it may not be
needed in all patients. An expert consensus on this issue
is lacking. Furthermore, the iso-osmolar media generally
have higher viscosity than their low-osmolar monomeric
counterparts. Hence, these media should be prewarmed
before infusion, which markedly lowers the viscosity [50].
6. Risk Assessment andScoring Systems
Patients usually have a combination of risk factors predis-
posing them to CIN after PCI. All scoring systems, therefore,
attempt to encompass these risk factors. Bartholomew et
al. worked on developing a time insensitive scoring system
[51]. Independent variables (with weighted scores) included
estimated creatinine clearance <60mL/min (2), urgent PCI
(2), intra-aortic balloon pump use (2), diabetes mellitus4 Cardiology Research and Practice
Table 2: Properties of contrast media.
Generic name Osmolarity Ionicity Viscosity (mPa.s at 20 C)
Diatrizoate n/a§
Iothalamate High-osmolar Ionic monomer n/a§
Ioxithalamate 26.0
Ioxaglate Ionic dimer 15.7
Iohexol 20.4
Iopamidol Low-osmolar 20.9
Ioversol Nonionic monomer 18.0
Iopromide 22.0
Iobitridol n/a§
Iomeprol n/a§
Iodixanol Iso-osmolar Nonionic dimer 26.6
§Not Available.
Table 3: Risk score for prediction of contrast-induced nephropathy
by Mehran et al. [35]. IABP, intra-aortic balloon pump; CHF,
congestive heart failure; eGFR, estimated glomerular ﬁltration rate.
Reprinted from [35].
(a)
Risk factors Score
Hypotension 5
IABP 5
CHF 5
Age>75 4
Anemia 3
Diabetes 3
Contrast volume 1/100 cc
Serum Cr> 1.5 4
OR
GFR<60mL/min/1.73m2 2 for 40–60
4 for 20–40
6f o r<20
(b)
Risk score Risk of CIN Risk of dialysis
<5 7.5% 0.04%
6–10 14% 0.12%
11–16 26.1% 1.09%
>16 57.3% 12.6%
(1), congestive heart failure (1), hypertension (1), peripheral
vascular disease (1), and contrast volume >260mL (1).
Incidence of CIN in their study was 2% [51].
Mehran et al., similarly, found eight variables (hypoten-
sion, intra-aortic balloon pump, congestive heart failure,
chronic kidney disease, diabetes, age >75 years, anemia, and
volume of contrast) and assigned a weighted integer to each
variable to make up a score cumulatively so as to divide
low risk (≥5) and high risk (≥16) scores [35]. The overall
occurrenceofCINinthedevelopmentsetwas13.1%.Table 3
shows their algorithm.
7.Prognosis
CIN is the leading cause of acute renal failure in hospitalized
patients and associated with prolonged in-hospital stay and
increased morbidity, mortality, and costs. A considerable
fraction of this in-hospital development of ARF has been
due to the use of contrast media in radiographic procedures
[29, 52]. In their retrospective analysis of the Mayo Clinic
PCI registry, Rihal et al. found that 22% of the patients with
ARF died during the index hospitalization compared with
only 1.4% of patients without ARF (P<. 0001). One-year
and 5-year estimated mortality rates were also signiﬁcantly
higher in patients with ARF [17]. Mortality ramped up not
only with ARF but even more if dialysis was needed as shown
by McCullough et al. [29].
A retrospective analysis of 16,248 patients exposed to
contrast media showed that even apparently small decreases
in renal function can lead to excessive mortality rates
independentofotherriskfactors,andgiventhatsmallrisesin
serum creatinine levels actually represent a signiﬁcant drop
inGFR[53].Furthermore,renalinsuﬃciencyhasbeenfound
tobeastrongindependentpredictorofdeathandsubsequent
cardiac events in a dose-dependent fashion during and after
PCI [54].
8. Prevention of Radiocontrast Nephropathy
8.1.VolumeAdministration. Volumeadministrationremains
the key factor for the prevention of CIN, even though
no randomized controlled trial has compared a strategy of
volume expansion with no volume expansion has been per-
formed. Possible mechanisms for prevention of renal insult
by ﬂuid administration include plasma volume expansion
with concomitant suppression of the rennin-angiotensin-
aldosterone system with the increased delivery of Na to
distal nephron, downregulation of the tubuloglomerular
feedback, dilution of the CM, and thus prevention of
renal cortical vasoconstriction—and avoidance of tubular
obstruction [55]. It may also be due to reduction in Nitric
Oxide production.Cardiology Research and Practice 5
Several trials have assessed the optimum type, amount,
duration, and route of ﬂuid administration to prevent
CIN [56–59]. However, much of these aspects remain
unclear.
Trivedi et al. found that oral ﬂuid administration alone
appeared to be inferior to intravenous volume expansion
with respect to the development of CIN [59]. Solomon
et al. demonstrated the superiority of intravenous 0.45%
Saline administration (starting 4–6 hours preprocedure and
continued for 24 hours postprocedure) over IV Saline plus
FurosemideandIVSalineandMannitolinpatientswithmild
renal insuﬃciency [56].
In a study conducted by Stevens et al., 98 participants
were randomized to forced diuresis with intravenous crys-
talloid, furosemide, mannitol (if pulmonary capillary wedge
pressure <20mmHg), and low-dose dopamine (n = 43)
versus intravenous crystalloid and matching placebos (n =
55). They showed that Plain IV Fluid administration is as
good as IV Fluid administration + Dopamine + Lasix +
Mannitol as long as urine ﬂow rates greater than 150mL/h
in the postprocedure period were achieved [57].
Recently, Mueller et al. showed that volume expansion
with isotonic saline is superior to half-isotonic saline, possi-
bly explained by its enhanced ability to expand intravascular
volume [60]. However, since this study was conducted on
low risk patients with normal renal function, these results
cannot be transferred conclusively to patients with moderate
and severe chronic renal failure.
The CIN Consensus Working Panel published strategies
to reduced contrast nephropathy a few years ago. Adequate
intravenousvolumeexpansionwithisotoniccrystalloid(1.0–
1.5mL/kg/hr) for 3–12 hours before the procedure and
continued for 6 to 24 hours to prevent development of
CIN in patients at risk. Caution is needed in patients
with CHF. They can beneﬁt from optimal hemodynamic
stabilization than excessive volume administration [61]. This
was supported by two further studies [62, 63].
Merten et al. found that volume expansion with sodium
bicarbonate (154mEq/L of sodium bicarbonate in dextrose
and water at a rate of 3mL/kg/hour per 1 hour before
CM exposure, followed by 1mL/kg/hour during, and for
6 hours after the procedure) was more eﬀective than with
sodium chloride for prophylaxis of contrast-induced renal
failure and may provide additional renoprotection by alka-
linizing renal tubular ﬂuid, which the authors hypothesized
would decrease tubular damage by scavenging oxygen free
radicals [64]. Over the years, a number of randomized
controlled trials comparing volume administration regimens
using sodium bicarbonate and sodium chloride have given
conﬂicting results, [65–69] with systematic reviews and meta
analyses performed on these trials inconsistently reporting
superiorityofsodiumbicarbonateoversodiumchloride[70–
72]. This may be due to heterogeneity between trials and the
large number of unpublished studies. Also, Zoungas et al., in
their systematic review found that smaller studies measuring
outcome relatively early were prone to report superiority
of sodium bicarbonate whereas larger studies provided
more neutral results between the two ﬂuid administration
regimens [72].
Finally, Clavijo et al. conducted a retrospective analysis
and demonstrated that a rapid intraarterial infusion of dex-
trose5%(1Ladministeredthroughthefemoralarterysheath
as a bolus >5 minutes immediately before angiography) was
well tolerated and eﬀective against CIN in patients with a
creatinine clearance ≤60mL/min [73].
Although, the key is adequate volume expansion for
the prevention of CIN, the prognostic implication of this
strategy, however, is missing. There is also a lack in suﬃcient
data to support a single best volume administration strategy
(optimal timing, type, volume, and rate of ﬂuid admin-
istration). Current evidence remains uncertain about any
superiority of sodium bicarbonate over sodium chloride in
preventing the development of CIN. Also, special emphasis
is needed on patients with heart failure and preexisting
renal failure as these patients are high risk for CIN and
have been poorly represented in existing studies on volume
administration. Also, these patients will be more challenging
in subjecting to high volume expansion.
8.2. Acetylcysteine. So far, N-acetylcysteine (NAC) has been
the most widely studied of all prophylaxis strategies. Several
possible mechanisms exist by which this drug protects
renal tissue from CM. One such mechanism is by direct
vasodilation of kidney vessels, contributing to improved
renal hemodynamics [74]. It may also decrease endothelial
dysfunction, and, most importantly, it is able to scavenge
oxygen free radicals, thus preventing direct oxidative tissue
damage occurring in patients receiving CM. This property of
NAC as an antioxidant gave it a popularity as a promising
drug for prevention of CIN.
In a landmark randomized placebo controlled trial
conducted by Tepel et al., it was ﬁrst seen that prophylactic
oral administration of the antioxidant acetylcysteine, along
with ﬂuid administration, prevented the reduction in renal
function induced by contrast agents in patients with chronic
renal insuﬃciency [75]. They showed that the incidence
of CIN as well as the decrease in mean serum creatinine
concentration 48 hours after administration of CM was
signiﬁcantly less in the acetylcysteine group. This beneﬁt was
conﬁrmed by the Acetylcysteine to Prevent Angiography-
Related Renal Tissue Injury (APART) trial, which showed
that NAC reduced the risk of postcardiac catheterization
nephropathy in patients with chronic renal insuﬃciency and
decreased ejection fraction [76]. Thus, it was considered as
routine prophylaxis in patients with chronic renal insuﬃ-
ciency undergoing cardiac catheterization.
However, recently, there has been a declining enthusiasm
for the eﬃcacy of NAC as numerous studies have failed
to show a signiﬁcant beneﬁt of acetylcysteine compared to
controls (Table 4)[ 77–82].
Researchers then investigated whether increasing the
standard dose of acetylcysteine (600mg orally twice daily)
resulted in better renoprotection. Hence, Briguori et al., in
their single center study, found that double dose of NAC
(1200mg orally twice daily) resulted in better prevention
of CIN, especially with high volumes (140mL) of non-
ionic, low-osmolality contrast agent [83]. Eﬃcacy of IV6 Cardiology Research and Practice
Table 4: Studies comparing acetylcysteine administration to control arm in patients undergoing coronary angiography.
Study (N) CIN deﬁnition Acetylcysteine Control P value
Azmus [77] (397) ≥25% or ≥0.5mg/dL, increase in SCr at 48 hours 7.1 8.4 .62
Boccalandro [81] (179) ≥0.5mg/dL increase in SCr at 48 hours 13 12 .84
Briguori [82] (183) ≥25% increase in Scr at 48 hours 65 11 .22
Kay [79] (200) ≥25% increase in SCr at 48 hours 4 12 .03
Marenzi [78] (354) ≥25% increase in SCr at 72 hours 15 versus 8a 30 <.001
Webb [80] (487) >5mL/min decrease in CrCl 23.3 20.7 .57
CIN, contrast-induced nephropathy; CrCl. Creatinine clearance; IV, intravenous; SCr, serum creatinine, dd, double dose
aThree arm study: standard dose versus high dose versus placebo.
acetylcysteine was investigated by Baker et al. in their RAP-
PID trial [84]. They randomised 80 patients with stable renal
dysfunction undergoing cardiac catheterization/intervention
to a rapid protocol of IV NAC (150mg/kg over 30 minutes
immediately before contrast followed by 50mg/kg over
4 hours) or IV ﬂuid administration (1mL/kg/h N/saline
for 12 hours pre- and postcontrast) and followed them
prospectively for development of Radiocontrast-induced
nephropathy. Even though NAC infusion was ceased after
the bolus in three patients (7%) due to ﬂushing, itching,
or a transient rash, overall, the trial showed a signiﬁcantly
lower incidence of CIN in treated patients as compared with
controls (5% versus 21%; P 1/4 0.04). Therefore, IV NAC
emerged as a reasonable option in all patients at risk of CIN
before contrast exposure when time constraints preclude
adequate oral prophylaxis, provided that the patient is able
to tolerate this degree of volume loading [84].
A meta-analysis of twenty trials involving 2195 patients
showed summary risk ratio for contrast-related nephropathy
to be 0.73 (95% conﬁdence interval: 0.52 to 1.0; P = .08),
a nonsigniﬁcant trend towards beneﬁt in patients treated
with acetylcysteine [85]. Meta-analyses generally conclude
that there may be some beneﬁt of NAC in reducing CIN
[85, 86]. These trials were, however, very heterogeneous with
inconsistent results. High-quality, large clinical trials that are
needed before acetylcysteine use in this indication can be
recommended universally.
Moreover, recent studies have assessed combined eﬃcacy
of two most important preventive interventions, use of NAC
and bicarbonate [62, 63]. These included the REMEDIAL
trial that showed the strategy of volume supplementation
by sodium bicarbonate plus NAC to be superior to the
combination of normal saline with NAC alone or with the
addition of ascorbic acid in preventing CIN in patients
at medium-to-high risk [62]. However, Maioli et al. had
contradicting results in their prospective single center study
including 502 patients with renal dysfunction with no
advantage of NAC and Sodium Bicarbonate to NAC and
Saline administration [87].
8.3.Statins. Statinshavealsobeenstudiedaspotentialagents
to prevent CIN in patients undergoing PCI, primarily by
means of their beneﬁcial eﬀects on endothelial function and
oxidative stress. This is very promising as most patients
undergoing PCI are already on this class of drugs. Patti et al.
showed that Statin-treated patients had a signiﬁcantly lower
incidence of CIN (3% versus 27%, P<. 0001; 90% risk
decrease) and had better postprocedural creatinine clearance
(80 ± 20 versus 65 ± 16mL/min, P<. 0001). Beneﬁt
of statin before treatment was observed in all subgroups,
except in patients with a preexisting creatinine clearance
<40mL/min [88]. Similar results were obtained in two
other large retrospective studies [89, 90]. However, in the
prospective, randomized, double-blind, placebo-controlled,
2-center PROMISS trial, involving 247 consecutive patients,
Simvastatin pretreatment for short term at high dose did not
prevent renal function deterioration after administration of
contrast medium in patients with baseline renal insuﬃciency
undergoing coronary angiography. Another prospective,
randomized, placebo control trial, involving 304 patients
with baseline Chronic Kidney Disease, did not demonstrate
any additional beneﬁt of 80mg Atorvastatin pretreatment
for the prevention of CIN in these patients [91]. However,
a prospective randomized trial showed favourable results
while using high dose Simvastatin (80mg) pretreatment
instead of low dose (20mg) to prevent CIN [92]. Overall,
strong evidence is not present to support the use of statins,
especially in patients where it is not otherwise indicated.
8.4. Other Interventions. Numerous other interventions have
been studied to assess their eﬃcacy in preventing CIN. Over-
all, results have either been ambiguous or unsatisfactory. A
list of these potential management strategies and the existing
data is summarized in Table 5.
9. Gadolinium
Gadolinium is often used as an alternative to iodinated
contrast in patients at increased risk of CIN. Overall, the
trials show conﬂicting results about whether gadolinium is
better than iodinated contrast in its risk of CIN (Table 6).
The safety of gadolinium in patients at increased risk of
CIN has not been established yet. In their systemic review
of 17 studies, Boyden et al. reported both favourable and
negative results with regard to the association of gadolinium
and CIN. The diﬀerences in the results appeared to be dose
related. When gadolinium was used in doses of 0.4mmol/kg
or higher, there appeared to be an increased incidence
of ARF particularly in patients with preexisting renal
insuﬃciency [116]. Furthermore, the risk of precipitatingCardiology Research and Practice 7
Table 5: List of agents assessed for prevention of CIN and the literature available on each.
Agent Mechanism Comment
Dopamine [93–95] Renal vasodilatation No clear beneﬁt
Deleterious in PVD
Fenoldopam [96–98] Selective dopa 1 receptor agonist No clear beneﬁt
May be intrarenal at higher doses
Theophylline [95, 99–101] Adenosine receptor antagonist No clear beneﬁt
Calcium Channel Blockers [102–104] Relieve vasoconstriction No clear beneﬁt
Prostaglandin E [105] Vasodilatation May be beneﬁcial
Ascorbic Acid [106] Antioxidant May be beneﬁcial
ANP [107] Vasodilatation No beneﬁt
Hemodialysis [108, 109]R e m o v a l o f o ﬀending agent No beneﬁt
Hemoﬁltration [110, 111] Continuous May be beneﬁcial
Table 6: Studies assessing incidence of CIN in patients with exposure of gadolinium as contrast.
Study Sample design Contrast dose Renal status CIN deﬁnition Renal outcome Preventive
treatment used
Spinosa
(2000)
[112]
35-Randomized
0.29mmol/kg (0.13–
0.40mmol/kg)
Gadolinium; 51mL
(33–80mL)
nonionic contrast
Cr > 1.5mg/dL
>0.5mg/dL increase
in [Cr ] within 48
hours
5 % (1/20) exposed to
Gadolinium; 40%
(6/15) exposed to
nonionic contrast
Volume
administration
Erley (2004)
[113]
21-Prospective,
randomized study
0.57 ±0.17mmol/kg
Gadolinium; 0.60 ±
0.271mmol/kg
Iohexol
Cr > 1.5mg/dL or
GFR < 50mL/min
>50% decrease in
GFR
50% (5/10) exposed to
Gadolinium and 45%
(5/11) exposed to
Iohexol
Volume
administration
Briguori
(2006)
[114]
57-Retrospective
study
0.6 ±0.3mmol/kg
Gadolinium based;
122 ±58mL
Iodixanol
Cr > 2mg/dLor
CrCL < 40mL/min
>0.5 mg/dL increase
in [Cr ] within 48
hours or need for
dialysis within 5
days
28% (7/ 25) exposed to
Gadolinium plus
iodinated contrast and
6.5% (2/32) exposed to
iodinated contrast
alone
Normal saline
plus N-
acetylcysteine
Reed (2007)
[115]
169-Retrospective
Study
151 ±79mL
Gadolinium (with
Iodinated contrast
dilution);
136 ±72mL
iodinated contrast
CrCl <
60mL/min/1.73m2,
a serum Cr level
>1.5mL/dL, and not
on hemodialysis.
≥0.5mg/dL increase
in [Cr] within 5 days
16% (14/90) of those
exposed to diluted
Gadolinium and 14%
(11/79) of Iodinated
contrast
N-
acetylcysteine
plus Volume
administration
Kane [38]
(2008)
163-Retrospective
Study
3c o m p a r a t i v e
groups receiving
76 ±40mL
Gadolinium; 55 ±35
Gadolinium (with
37 ±37 Iodinated
contrast); 102 ±50
Iodinated contrast
Cr ≥ 2mg/dL
≥0.5mg/dL increase
in [Cr] within 7 days
5.3% (3/57) in
Gadolinium only;
10.5% (4/38) in
Gadolinium +
Iodinated Contrast;
20.6% (14/68) in
Iodinated contrast
alone
N-
acetylcysteine
plus Volume
administration
CrCL: Creatinine Clearance; Cr: Serum Creatinine GFR: Glomerular Filtration Rate.
nephrogenic systemic ﬁbrosis (NSF) through administration
ofGadoliniuminpatientsalreadyrenallycompromisedmust
be emphasized [117]. NSF seems to be associated with
administration of higher than usual doses of Gadolinium,
according to one study [118]. Hence, till further evidence
becomesavailable,administrationofGadoliniumtodecrease
CIN incidence appears questionable, especially in the light of
its particular adverse eﬀects.
10. Conclusion
CIN is an iatrogenic disorder with high morbidity and
mortality and a high incidence in elderly, diabetics, and
patients with pre existing renal failure. Despite uncertainty
regarding the degree of nephrotoxicity produced by vari-
ous contrast agents, nonionic low-osmolar or iso-osmolar
contrast media remains the preferred choice. Limiting the8 Cardiology Research and Practice
volume of contrast as much as possible is recommended.
Best way to prevent CIN is to identify patients at high risk
and provide adequate volume administration. However, use
of sodium bicarbonate or N-Acetylcysteine in its prevention
remains inconclusive in light of available evidence. Although
theroleofvariousdrugsinpreventionremainscontroversial,
nephrotoxic drugs should be avoided before and after the
procedure. Also, there still is no conclusive evidence to
recommend gadolinium as a better alternative to iodinated
contrast media in order to prevent CIN.
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